ClinicalTrials.gg
CompletedNCT04147325Updated Dec 11, 2023

A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1

An observational study in HIV, sponsored by Janssen-Cilag Farmaceutica Ltda.. Completed at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the proportion of newly diagnosed participants with Human Immunodeficiency Virus (HIV)-1 (naive participants) with virologic response at Week 48-defined as HIV-1 Ribonucleic acid (RNA) less than (\<) 50 copies/milliliter (mL) (Food And Drug Administration snapshot) - after the implementation of the Test \& Treat model of care and in a historical cohort.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Janssen-Cilag Farmaceutica Ltda. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, who will be included in a Test and Treat model of care (Prospective Cohort) and naive HIV-infected participants who had their first care visit at the outpatient clinic of the center through 2017 (Retrospective Cohort) will be observed. Only data available as per clinical practice will be collected within this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prospective cohort: Newly diagnosed with (HIV)-1 evidenced by any of the following: or HIV Rapid Antibody positive; HIV Immunoassay positive; positive HIV (p24) antigen; or detectable HIV-1 Ribonucleic acid (RNA) Viral Load and non-reactive antibody/antigen assays. HIV-1 RNA Viral Load must be confirmed within one week of initial HIV-1 RNA Viral Load test
  • Prospective cohort: Antiretroviral (ARV) treatment-naïve who will initiate treatment. Retrospective cohort: Dates of HIV-1 diagnosis and ARV treatment initiation available in clinical records
  • Prospective and Retrospective cohorts: Must sign [and/or their legally-acceptable representative where applicable must sign,] a participation agreement/ Form (ICF) allowing data collection and source data verification in accordance with local requirements

Exclusion criteria

Exclusion Criteria:

  • Known Acquired Immune Deficiency Syndrome (AIDS)-defining condition
  • Known history of hepatic disease or hepatitis that in the investigator's judgement is not compatible with Antiretroviral Therapy (ART)
  • Known history of chronic renal insufficiency, defined as having an less than (\<) 50 milliliter/minute (ml/min) according to the formula
  • Known active severe infections (other than -1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to screening
  • Known history of cirrhosis as diagnosed based on local practices
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (actual)
Patient registry
No

Groups and cohorts

  • Prospective Cohort

    Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, will receive Antiretroviral Therapy (ART) in accordance with clinical practice and will be included in a Test and Treat model of care at the outpatient clinic of the center.

    Drug: Antiretroviral Therapy

  • Historical Cohort

    Naive HIV-1 infected participants who had their first care visit at the outpatient clinic of the center through 2017 will be included in this cohort.

    Drug: Antiretroviral Therapy

Interventions

  • DrugAntiretroviral Therapy

    ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.

06

What researchers measure

Primary outcomes

  1. Percentage of Newly Diagnosed Participants with Human Immunodeficiency Virus (HIV)-1 Ribonucleic acid (RNA) < 50 Copies per Milliliter (c/mL) at Week 48 (Virologic Response)

    The percentage of newly diagnosed participants is defined as the percentage of newly HIV-1 infected participants that are considered virologic responders (that is have HIV-1 RNA viral load less than \[\<\] 50 c/mL) at Week 48 as per the Food And Drug Administration (FDA) snapshot algorithm.

    Time frame: Week 48

Secondary outcomes

  1. Time to Antiretroviral Therapy (ART) Initiation since HIV-1 Diagnosis

    Time to ART initiation is defined as time from HIV diagnosis (date of the first HIV positive test) to the start of ART.

    Time frame: Up to 48 weeks

  2. Time to Virologic Suppression

    Time to virologic suppression is defined as time from start of ART to the HIV RNA \< 50 copies/mL measured as per FDA snapshot algorithm.

    Time frame: Up to 48 weeks

  3. Time to Virologic Response

    Time to virologic response is defined as HIV-1 RNA viral load (VL) \< 200 copies/mL measured as per FDA snapshot algorithm.

    Time frame: Up to 48 weeks

  4. Change from Baseline in HIV-1 RNA from Start of ART

    Change from baseline in HIV-1 RNA will be assessed through time (up to Week 48) from the date of start of ART.

    Time frame: Baseline up to week 48

  5. Change from Baseline in Cluster Differentiation 4 (CD4) Cell Count

    Change from baseline in CD4 cell count for immunologic changes after ART initiation will be determined.

    Time frame: Baseline up to Week 48

  6. Change from Baseline in Viral Load

    Change from baseline in viral load for virologic changes after ART initiation will be determined.

    Time frame: Baseline up to Week 48

  7. Percentage of Participants not Lost-to-Follow up

    The percentage of participants who maintained regular visits to the HIV center during a 12-month period after HIV diagnose period will be reported.

    Time frame: 12 months

  8. Time from HIV Diagnosis to First Care Visit

    Time from HIV diagnosis to first care visit will be performed by evaluating time between diagnosis of HIV and date of the first care visit.

    Time frame: Baseline (Day 1)

  9. Time from First Care Visit to ART Initiation

    Time from first care visit to ART initiation in all newly diagnosed patients with HIV will be reported.

    Time frame: Baseline (Day 1)

  10. Percentage of Participants Developing PR, RT, and INI Resistance-Associated Mutation (RAMs) During Follow-up

    Percentage of participants developing protease (PR), reverse transcriptase (RT), and integrase (INI) RAMs during follow-up will be reported.

    Time frame: Through 4, 6, 12, 24 and 48 weeks

  11. Percentage of Participants who Loss-to-Follow According to Burkitt lymphoma (BL) CD4 cell Count

    Percentage of participants who lost-to-follow up according to BL CD4 cell count, in all newly diagnosed participants with HIV will be reported.

    Time frame: Up to 24 Months (end of study)

  12. Change from Baseline in ARV Regimen due to Resistance

    Changes from baseline in ARV regimen due to resistance, will be evaluated in all newly diagnosed participants with HIV.

    Time frame: Baseline up to Week 48

07

Study locations

1 site
  • Chlo - Hosp. Egas Moniz
    Lisboa, 1349-019, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Dec 2022, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2019
First posted
Nov 1, 2019
StartActual
Dec 17, 2019
Primary completionActual
Dec 12, 2022
CompletionActual
Dec 12, 2022
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04147325
Responsible party
Sponsor
First posted
Nov 1, 2019
Start date
Dec 17, 2019
Primary completion
Dec 12, 2022
Completion
Dec 12, 2022
Last update
Dec 11, 2023

Study contacts

Janssen-Cilag Farmaceutica Ltda. Clinical Trial
study director · Janssen-Cilag Farmaceutica Ltda.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion